Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors

European Journal of Clinical Pharmacology

Volumn 64, Issue 11, 2008, Pages 1047-1056

  Johnson, L'Aurelle A ^a   Oetting, William S ^a   Basu, Saonli ^a   Prausa, Susie ^b   Matas, Arthur ^c   Jacobson, Pamala A ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Kidney transplantation; Mycophenolate; Pharmacogenetics; Polymorphisms; Uridine diphosphate glucuronosyltransferase

Indexed keywords

ALBUMIN; ALEMTUZUMAB; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 1A9; HEMOGLOBIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GRAFT REJECTION; HEMATOCRIT; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY TRANSPLANTATION; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PANCREAS TRANSPLANTATION; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; AGED; CALCINEURIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; KIDNEY TRANSPLANTATION; LINEAR MODELS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 55349089900     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-008-0501-y     Document Type: Article

References (36)

1. LM Shaw M Korecka R Venkataramanan L Goldberg R Bloob KL Brayman 2003 Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies Am J Transplant 3 534 542
2. RE Bullingham AJ Nicholls BR Kamm 1998 Clinical pharmacokinetics of mycophenolate mofetil Clin Pharmacokinet 34 429 455
3. MD Hale AJ Nicholls RE Bullingham R Hene A Hoitsma JP Squifflet W Weimar Y Vanrenterghem FJ Van de Woude GA Verpooten 1998 The pharmacokinetic- pharmacodynamic relationship for mycophenolate mofetil in renal transplantation Clin Pharmacol Ther 64 672 683
4. M Mourad J Malaise D Chaib Eddour M De Meyer J Konig R Schepers JP Squifflet P Wallemacq 2001 Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil Clin Chem 47 88 94
5. T van Gelder Y Le Meur LM Shaw M Oellerich D DeNofrio C Holt DW Holt B Kaplan D Kuypers B Meiser B Toenshoff RD Mamelok 2006 Therapeutic drug monitoring of mycophenolate mofetil in transplantation Ther Drug Monit 28 145 154
6. RM van Hest DA Hesselink AG Vulto RA Mathot T van Gelder 2006 Individualization of mycophenolate mofetil dose in renal transplant recipients Expert Opin Pharmacother 7 361 376
7. M Naesens DR Kuypers K Verbeke Y Vanrenterghem 2006 Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients Transplantation 82 1074 1084
8. DA Hesselink T van Gelder 2005 Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid Clin Pharmacol Ther 78 317 321
9. CP Strassburg K Oldhafer MP Manns RH Tukey 1997 Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: Identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue Mol Pharmacol 52 212 220
10. K Bowalgaha JO Miners 2001 The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes Br J Clin Pharmacol 52 605 609
11. CP Strassburg MP Manns RH Tukey 1998 Expression of the UDP-glucuronosyltransferase 1A locus in human colon identification and characterization of the novel extrahepatic UGT1A8 J Biol Chem 273 8719 8726
12. RH Tukey CP Strassburg 2000 Human UDP-glucuronosyltransferases: Metabolism, expression, and disease Annu Rev Pharmacol Toxicol 40 581 616
13. Z Cheng A Radominska-Pandya TR Tephly 1998 Cloning and expression of human UDP-glucuronosyltransferase (UGT) 1A8 Arch Biochem Biophys 356 301 305
14. H Girard MH Court O Bernard LC Fortier L Villeneuve Q Hao DJ Greenblatt LL von Moltke L Perussed C Guillemette 2004 Identification of common polymorphisms in the promoter of the UGT1A9 gene: Evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver Pharmacogenetics 14 501 515
15. O Bernard C Guillemette 2004 The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants Drug Metab Dispos 32 775 778
16. DR Kuypers M Naesens S Vermeire Y Vanrenterghem 2005 The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients Clin Pharmacol Ther 78 351 361
17. YH Huang A Galijatovic N Nguyen D Geske D Beaton J Green M Green WH Peters RH Tukey 2002 Identification and functional characterization of UDP-glucuronosyltransferases UGT1A8*1, UGT1A8*2 and UGT1A8*3 Pharmacogenetics 12 287 297
18. Bernard O, Tojcic J, Journault K, Perusse L, Guillemette C (2006) Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid. Drug Metab Dispos 34:1539-1545
19. PA Jacobson KG Green BJ Hering 2005 Mycophenolate mofetil in islet cell transplant: Variable pharmacokinetics but good correlation between total and unbound concentrations J Clin Pharmacol 45 901 909
20. UA Argikar JC Cloyd AK Birnbaum IE Leppik J Conway S Kshirsagar WS Oetting EC Klein RP Remmel 2006 Paradoxical urinary phenytoin metabolite (S)/R) ratios in CYP2C19*1/*2 patients Epilepsy Res 71 54 63
21. H Kagaya K Inoue M Miura S Satoh M Saito H Tada T Habuchi T Suzuki 2007 Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients Eur J Clin Pharmacol 63 279 288
22. E Levesque R Delage MO Benoit-Biancamano P Caron O Bernard F Couture C Guillemette 2007 The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers Clin Pharmacol Ther 81 392 400
23. M Saeki Y Saito H Jinno K Sai S Ozawa K Kurose N Kaniwa K Komamura T Kotake H Morishita S Kamakura M Kitakaze H Tomoike K Shirao T Tamura N Yamamoto H Kunitoh T Hamaguchi T Yoshida K Kubota A Ohtsu M Muto H Minami N Saijo N Kamatani JI Sawada 2006 Haplotype structures of the UGT1A gene complex in a Japanese population Pharmacogenomics J 6 63 75
24. K Zucker A Rosen A Tsaroucha L de Faria D Roth G Ciancio V Esquenazi G Burke A Tzakis J Miller 1997 Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings Transpl Immunol 5 225 232
25. E Vidal C Cantarell L Capdevila V Monforte A Roman L Pou 2000 Mycophenolate mofetil pharmacokinetics in transplant patients receiving cyclosporine or tacrolimus in combination therapy Pharmacol Toxicol 87 182 184
26. K Zucker A Tsaroucha L Olson V Esquenazi A Tzakis J Miller 1999 Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation Ther Drug Monit 21 35 43
27. K Zucker A Rosen A Tsaroucha L de Faria D Roth G Ciancio V Esquenazi G Burke A Tzakis J Miller 1997 Augmentation of mycophenolate mofetil pharmacokinetics in renal transplant patients receiving prograf and CellCept in combination therapy Transplant Proc 29 334 336
28. T Naito K Shinno T Maeda Y Kagawa H Hashimoto A Otsuka T Takayama T Ushiyama K Suzuki S Ozono 2006 Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation Biol Pharm Bull 29 275 280
29. DA Hesselink RM van Hest RA Mathot F Bonthuis W Weimar RW de Bruin T van Gelder 2005 Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2 Am J Transplant 5 987 994
30. V Kumar CW Locuson YY Sham TS Tracy 2006 Amiodarone analog-dependent effects on CYP2C9-mediated metabolism and kinetic profiles Drug Metab Dispos 34 1688 1696
31. N Picard N Djebli FL Sauvage P Marquet 2007 Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5 Drug Metab Dispos 35 350 355
32. N Djebli N Picard JP Rerolle Y Le Meur P Marquet 2007 Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on acyl-MPAG production in vitro and in adult renal transplant patients Pharmacogenet Genomics 17 321 330
33. DR Kuypers K Claes P Evenepoel B Maes W Coosemans J Pirenne Y Vanrenterghem 2003 Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: A prospective study in 100 de novo renal allograft recipients J Clin Pharmacol 43 866 880
34. RM van Hest RA Mathot MD Pescovitz R Gordon RD Mamelok T van Gelder 2006 Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: A population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients J Am Soc Nephrol 17 871 880
35. R Borrows G Chusney M Loucaidou A James J Lee JV Tromp J Owen T Cairns M Griffith N Hakim A McLean A Palmer V Papalois D Taube 2006 Mycophenolic acid 12-h trough level monitoring in renal transplantation: Association with acute rejection and toxicity Am J Transplant 6 121 128
36. N Picard D Ratanasavanh A Premaud Y Le Meur P Marquet 2005 Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism Drug Metab Dispos 33 139 146